These two BRs were also analyzed for the anticancer effects in the breast cancer cell lines MDA-MB-468 (estrogen receptor-α-negative) and MCF-7 (estrogen receptor-α-positive), and prostate cancer cell lines DU-145 (androgen-insensitive), and LNCaP (androgen-sensitive). Here, ESR1 is linked to breast carcinoma.